
Opinion|Videos|August 7, 2024
First-Line Immune Checkpoint Inhibitors for Poor Risk Metastatic RCC
Key opinion leaders in renal cell carcinoma provide a comprehensive overview of first-line immune checkpoint inhibitor combination regimens for patients with intermediate-to-poor risk metastatic renal cell carcinoma.
Episodes in this series





































